<DOC>
	<DOC>NCT01609231</DOC>
	<brief_summary>The purpose of this adaptive trial is to compare the progression-free survival of participants with metastatic rectal carcinoma when treated with dalotuzumab + irinotecan therapy relative to participants treated with cetuximab + irinotecan.</brief_summary>
	<brief_title>A Trial of Dalotuzumab in Combination With Irinotecan Versus Cetuximab and Irinotecan for Participants With Metastatic Rectal Cancers (mRC) (MK-0646-025)</brief_title>
	<detailed_description />
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Metastatic colorectal cancer with primary tumor originating from the rectum Available archival (recent or remote) tumor, or newly obtained formalinfixed tissue available for analysis for biomarker studies At least one measurable lesion greater than or equal to 10 mm Disease has progressed after treatment with both irinotecan and oxaliplatin containing regimens and should have progressed on or within 3 months of completing their last line of therapy Performance status 01 on the Eastern Cooperative Oncology Group (ECOG) Performance Scale Known diabetic who is poorly controlled Chemotherapy or biological therapy within 2 weeks prior to initial dosing on this study, or whose toxicities from agents administered 2 weeks earlier have not resolved to at least grade 1 or baseline, or who is within 3 weeks from a prior surgery Radiotherapy within 2 weeks prior to initial dosing on this study, unless the radiotherapy was for management of pain Currently participating or has participated in a study with an investigational compound or device within 30 days or 5 halflives of the investigational agent, whichever is longer, of initial dosing on this study Could not complete previous course of irinotecan due to intolerable toxicity, other than discontinuation due to fatigue following prolonged administration (&gt;4 months exposure) Prior exposure to insulinlike growth factor 1 receptor (IGF1R) inhibitors or epidermal growth factor receptor (EGFR) inhibitors Known Central Nervous System (CNS) metastases and/or carcinomatous meningitis Primary CNS tumor History of a prior malignancy with the exception of cervical intraepithelial neoplasia; basal cell carcinoma of the skin; adequately treated localized prostate carcinoma; potentially curative therapy with no evidence of that disease for 5 years, deemed low risk for recurrence by treating physician. Human Immunodeficiency Virus (HIV)positive Active Hepatitis B or C receiving antiviral treatment regimens Symptomatic ascites or pleural effusion Concurrently using growth hormone (GH), or growth hormone inhibitors</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>